Evidence map›Paper›PMID 36628029›Full record

ArticleCureus2022

Tardive Dyskinesia Following Low-Dose Risperidone.

Ahmad E Rokon, Faisal A Alsomali, Malek A Alrasheed, Abdulrahman D Alharbi, Moustafa S Alhamadh, Abdulmajeed M Alqahtani, Farah K Alhamidy, Meshal R Alotaibi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmad E RokonCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Faisal A AlsomaliCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Malek A AlrasheedCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Abdulrahman D AlharbiCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Moustafa S AlhamadhCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Abdulmajeed M AlqahtaniCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Farah K AlhamidyAdult Mental Health, King Abdulaziz Medical City, Riyadh, SAU.
Meshal R AlotaibiAdult Mental Health, King Abdulaziz Medical City, Riyadh, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tardive dyskinesia is an involuntary athetoid or choreiform movement lasting a minimum of a few weeks. It is associated with the use of neuroleptic medication for at least three months and persists beyond four to eight weeks. Tardive dyskinesia usually occurs as a result of the long-term use of dopamine receptor-blocking agents, mainly first-generation antipsychotics or a high-dose, second-generation antipsychotic. We present a case of a 28-year-old female with osteogenesis imperfecta presented later with major depressive disorder with psychotic features. She was given a low-dose second-generation antipsychotic, namely, risperidone (2 mg) for psychosis for a cumulative duration of three months. As a result, she developed extrapyramidal symptoms in the form of akathisia, axial dystonia, involuntary movement of the right hand, and smacking movement of the lips. Symptoms persisted for more than eight weeks despite discontinuing risperidone and switching to quetiapine. After the exclusion of other differential diagnoses, she was labeled as a case of tardive dyskinesia. More studies are needed to assess whether undiscovered contributing factors to tardive dyskinesia exist and to understand how second-generation antipsychotics (SGAs) contribute to the development of tardive dyskinesia.

Indexed as

extrapyramidal symptomsmovement disorderneurologypsychosistardive dyskinesia

Identifiers

PMID36628029
PMCPMC9825118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.